ALDX - Aldeyra Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5158.85M
Enterprise Value 3121.72M
Trailing P/E N/A
Forward P/E 1-2.81
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.31
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-2.61

Trading Information

Stock Price History

Beta (3Y Monthly) 1.07
52-Week Change 3-23.53%
S&P500 52-Week Change 34.18%
52 Week High 316.70
52 Week Low 34.31
50-Day Moving Average 35.11
200-Day Moving Average 36.80

Share Statistics

Avg Vol (3 month) 3247.36k
Avg Vol (10 day) 3283.03k
Shares Outstanding 527.58M
Float 20.12M
% Held by Insiders 11.94%
% Held by Institutions 173.18%
Shares Short (Aug 15, 2019) 41.01M
Short Ratio (Aug 15, 2019) 46.01
Short % of Float (Aug 15, 2019) 44.54%
Short % of Shares Outstanding (Aug 15, 2019) 43.68%
Shares Short (prior month Jul 15, 2019) 41.15M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-49.79%
Return on Equity (ttm)-96.63%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -46.57M
Net Income Avi to Common (ttm)-50.4M
Diluted EPS (ttm)-2.00
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)37.46M
Total Cash Per Share (mrq)1.36
Total Debt (mrq)327.87k
Total Debt/Equity (mrq)0.49
Current Ratio (mrq)11.40
Book Value Per Share (mrq)2.49

Cash Flow Statement

Operating Cash Flow (ttm)-41.1M
Levered Free Cash Flow (ttm)-38.65M